Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022
May 17, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
- Human equivalent ADVM-022 dose of 6E10 vg/eye provided therapeutic levels of aflibercept in NHPs - Oral encore presentation to highlight ADVM-022 reductions in mean annualized anti-VEGF...
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
May 17, 2022 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy...
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Adverum Biotechnologies Reports First Quarter 2022 Financial Results
May 12, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022 16:01 ET
|
Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2022 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Ocugen Provides Business Update and First Quarter 2022 Financial Results
May 06, 2022 06:33 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is...
IBN’s BioMedWire to Serve as Media Sponsor for the Upcoming 2nd Annual Gene Therapy Patient Engagement Summit
May 04, 2022 09:35 ET
|
InvestorBrandNetwork (IBN)
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- via BioMedWire -- IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
May 02, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
May 01, 2022 14:15 ET
|
Adverum Biotechnologies, Inc.
- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81%...